Applying quantitative proteomics for target system analysis in preclinical inflammatory bowel disease models

In this application note, Inotiv discusses the application of quantitative proteomics in preclinical studies of inflammatory bowel disease (IBD). IBD is a chronic autoimmune disorder that affects millions of people worldwide. Preclinical drug discovery and development programs for IBD usually employ rodent models that mimic clinical and histopathological features of IBD but differ in how they are generated and present distinct phenotypic characteristics. Using proteome analysis technology, Inotiv provides insights into the protein networks and pathways driving disease pathology and therapeutic response.